Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies related to our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products and uncertainty about the amount of revenue that we will receive from such agreements; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the uncertain effect of the Mirataz® to Dechra Pharmaceuticals PLC; the risk that the revenue from our delivery of services or products under any contract may be less than we anticipate if the other party to the contract exercises its right to terminate the contract prior to the completion of the contract; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this presentation. Forward-looking statements contained in this press release speak only as of the date of this presentation and we undertake no obligation to update or revise these statements, except as may be required by law.

The results stated in this presentation have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Growing Spend on Pet Family Members

We spend generously on pets...

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>$99.0 billion on Valentine’s Day presents</td>
<td></td>
</tr>
<tr>
<td>$1.7 billion on Halloween costumes for pets</td>
<td></td>
</tr>
<tr>
<td>$490 million on Valentine’s Day presents</td>
<td></td>
</tr>
</tbody>
</table>

...Because pets are family

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% of owners consider pets part of the family</td>
<td></td>
</tr>
<tr>
<td>35% of pet parents would give up their cell phone to pay for pet emergency</td>
<td></td>
</tr>
<tr>
<td>71% of pets sleep in bed with their pet parents</td>
<td></td>
</tr>
</tbody>
</table>


**34 MILLLION HOUSEHOLDS HAVE CHILDREN**

**85 MILLION HOUSEHOLDS HAVE PETS**

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>80% care for their pets like children</td>
<td></td>
</tr>
<tr>
<td>52% believe the quality of their pets’ food should exceed their own</td>
<td></td>
</tr>
<tr>
<td>43% buy non-essentials like toys on impulse</td>
<td></td>
</tr>
<tr>
<td>46% have purchased clothing or fashion accessories</td>
<td></td>
</tr>
</tbody>
</table>

85 MILLION HOUSEHOLDS HAVE PETS

**34 MILLION HOUSEHOLDS HAVE CHILDREN**
Unique Development Strategy

KindredBio Develops Innovative Biologics for Pets

- Average of $8M to develop a biologic in 6 years
- Reduce technical risk
- Shorten timelines
- Reduce financing risk
- Pursue targets known to work in humans
- Portfolio approach

Market sizes are 2 to 10-fold smaller than human markets, but the cost of development is 100-fold less.
Recession-Resistant Spend

Pet Industry Sales: Government Personal Consumption Expenditures ("PCE") and Industry Estimates

- **CONTINUED GROWTH DURING RECESSION**
- **Average Spend to Save Life of Pet (2)**
  - Cat Owners: $10,200
  - Dog Owners: $10,330
- **Low Generic Competition (3)**
  - **Generic Dispensing Rates**
    - Companion animal: 7%
    - Human: 81%

### Key Points:
- Few Generic Competitors
- No Automatic Substitution
- Peak Sales Often Reached Post Patent Expiration
- No Biosimilar Pathway

---

(1) U.S. Bureau of Economic Analysis (2018); American Pet Products Association (2018)
(2) www.lendedu.com/blog/how-much-are-dog-and-cat-owners-willing-to-spend
(3) Health, Putney BoA Merrill Lynch Global Research; note: Companion Animal dispensing rate within the veterinary clinic.
Canine Dermatitis - Large and Growing Market

Two recent drugs are selling >$900M a year (combined) and are growing.

Prevalence

Itch is #1 reason for canine veterinarian visits

Growing Market

47% increase in itchy dog veterinarian visits since 2014

Diagnosis

10-15% have atopic dermatitis, an allergic skin disease

Key Profit Center

83% of dogs seen by dermatologists suffer from pruritis (itch)

Sources:
March 2018 Webroot Pet Pet Pruritus Projection Total Report
Need for New Biologicals

GP veterinarians desire a new biological treatment option for pruritic dogs (70%)

Dermatologists desire a new biological treatment option for pruritic dogs (80%)

Not all products work for every patient

Treatment non-response rates as high as one in four patients, depending on allergy

Treating pruritis is multimodal and veterinarians desire more tools

TIRNOVETMAB: FULLY CANINIZED, HIGH-AFFINITY MONOCLONAL ANTIBODY TARGETING INTERLEUKIN-31

- Blocks IL-31, a key mediator of itching
- Positive results in pilot effectiveness study
- Achieved rapid and dramatic reduction in pruritus (itch) and CADESI-4 score versus placebo
- Pivotal study commenced in December 2020

Note: CADESI-4 = Canine Atopic Dermatitis Extent and Severity Index-4

The results stated in this slide have not been reviewed by the United States Department of Agriculture Center for Veterinary Biologics.
KIND-032 binds to the IL-4 receptor on the surface of immune cells

As a result of blockade of IL-4R, it prevents both IL-4 and IL-13 signaling pathways

Positive results from pilot laboratory study of IL-4R. Evidence of positive efficacy and dose response

Pilot study to further assess dosing commenced in 3Q 2020

Note: The results stated in this slide have not been reviewed by the United States Department of Agriculture Center for Veterinary Biologics.
PVAS score: Pruritic Visual Analog Scale
Deep Product Pipeline

PIPELINE COMPRISSES

INNOVATIVE BIOLOGICS

FOCUS ON

LATE STAGE PROGRAMS

MIX OF

NEW MODALITIES & GREENFIELD MARKETS

<table>
<thead>
<tr>
<th>MOLECULE</th>
<th>Proposed Indication</th>
<th>Preclinical</th>
<th>Laboratory Pilot Studies</th>
<th>Field Pilot Studies</th>
<th>Pivotal Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tirnovetmab (IL-31 antibody)</td>
<td>Atopic dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-4R antibody</td>
<td>Atopic dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KIND-030</td>
<td>Parvovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-TNF antibody</td>
<td>Inflammatory bowel disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other product candidates in development (partial list) include KIND-bodies, VEGF antibody, and Checkpoint Inhibitors. Does not include equine candidates.

Pipeline disclaimer: This material is intended to provide investors with information about KindredBio’s clinical development pipeline and is not intended for promotional purposes.
Agreements Validate Commercialization Strategy

Elanco granted exclusive global rights to KIND-030 (parvovirus) in return for development milestones ≤$16M, sales milestones ≤$94M & low to high teen royalty.

Dechra Pharmaceuticals granted exclusive marketing, sales & distribution rights to Zimeta, the first FDA-approved drug for the control of pyrexia in horses.

Sale of Mirataz to Dechra Pharmaceuticals for an upfront payment of $43 million & low teen royalty on worldwide sales. Mirtaz was developed for $5M in five years.
### Key Milestones

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Proposed Indication</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIND-030</td>
<td>Parvovirus in dogs</td>
<td>Positive pilot study results</td>
<td>Positive results from pivotal efficacy study (prophylactic therapy). Pivotal efficacy study for treatment indication expected in 2Q 2021. Commercialization agreement with Elanco</td>
</tr>
<tr>
<td>Tirnovetmab (IL-31 antibody)</td>
<td>Atopic dermatitis in dogs</td>
<td>Positive pilot study results</td>
<td>Pivotal efficacy study commenced in December 2020 and is ongoing</td>
</tr>
<tr>
<td>IL-4R antibody</td>
<td>Atopic dermatitis in dogs</td>
<td>Positive pilot study results</td>
<td>Pilot study to further assess dosing commenced in 3Q 2020</td>
</tr>
<tr>
<td>Anti-TNF antibody</td>
<td>Inflammatory bowel disease in dogs</td>
<td>Pilot study commenced</td>
<td>Positive results from pilot field effectiveness study in 4Q 2020</td>
</tr>
<tr>
<td>IL-4/13 SINK</td>
<td>Atopic dermatitis in dogs</td>
<td>Pilot study commenced</td>
<td>Positive study results in 1Q 2020</td>
</tr>
<tr>
<td>Mirataz® (mirtazapine transdermal ointment)</td>
<td>Control of weight loss in cats</td>
<td>Self-commercialization</td>
<td>Completed sale of Mirataz to Dechra for $43 million and global royalties in April 2020</td>
</tr>
<tr>
<td>Mirataz® EU</td>
<td>Bodyweight gain in cats</td>
<td>Approval</td>
<td>Commercial launch in the UK and EU by Dechra expected early in 2021</td>
</tr>
<tr>
<td>Zimeta™ (dipyrone injection)</td>
<td>Bodyweight gain in cats</td>
<td>Approval</td>
<td>Dechra granted exclusive marketing, sales &amp; distribution rights to Zimeta</td>
</tr>
</tbody>
</table>
Focus on Innovative Biologics
VETERINARY MEDICINE TO FOLLOW HUMAN MARKET, IN WHICH TOP DRUGS ARE BIOLOGICS

- Industry leading biologics programs
- Declining manufacturing costs make biologics competitive in animal health
- Administered in office, so veterinarian maintains revenue stream
- Highly experienced KindredBio team responsible for developing top human drugs
- End-to-end capabilities and new technologies (KIND-bodies)
Half-Life Extension

Typical canine antibodies have half-life of 9-12 days

KindredBio has developed technology to modify the Fc tail of antibodies to increase half-life to 3X normal

This could reduce frequency of administration by 3X and/or could lower cost of goods by 3X

The technology may work for other species

Long-acting versions of certain publicly disclosed molecules in development
Deep Pipeline
## Canine Parvovirus

### Highly Contagious Disease
Affects mostly puppies, with no approved therapies

### Disease Burden
Mortality rate as high as 91% if untreated; > 60% of shelter dogs lack adequate titers to protect against parvo

### Cost Burden
Supportive care can cost thousands, with average cost $1,200

### Market Opportunity
Approx. 250,000* canine parvovirus (CPV) cases in the US each year, excluding emergency hospitals, shelters, or undiagnosed cases. Veterinarians estimate about half infected puppies potentially expose other puppies, and each puppy has on average the potential to expose five others**

### Positive Pivotal Efficacy Results (Prophylactic)
Two indications being pursued: Prophylactic therapy after exposure and treatment of CPV after infection. In prophylactic study, all placebo-control dogs developed CPV infection, while none of the KIND-030 treated dogs developed the disease. Mortality benefit observed in treated group

### Regulatory Timeline
Completion of pivotal efficacy study for treatment indication expected in 2Q 2021

### Commercialization
Elanco granted exclusive global rights in return for development milestones of ≤$16M, sales milestones of ≤$94M and low to high teen royalty

---

Canine Inflammatory Bowel Disease

<table>
<thead>
<tr>
<th>Prevalence</th>
<th>Majority of cases involve chronic states of diarrhea, vomiting, gastroenteritis, and other symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diarrhea prevalence &gt;5%</td>
</tr>
<tr>
<td>Disease Burden</td>
<td>Chronic condition, with diagnosis common in middle age</td>
</tr>
<tr>
<td></td>
<td>Existing treatments can have significant drawbacks, leading to treatment lapses or poor quality of life</td>
</tr>
<tr>
<td>Cost Burden</td>
<td>High willingness to pay given impact on owner</td>
</tr>
<tr>
<td>Recent Catalyst</td>
<td>Positive results from pilot field effectiveness study. Complete remission* was achieved in 75% of the anti-TNFα group compared to 17% in the placebo group. The treatment effect was early-onset and durable</td>
</tr>
</tbody>
</table>

* Defined as ≥ 75% reduction in average post-dose Canine Inflammatory Bowel Disease Activity Index (CIBDAI) score from baseline
First Approvals
**Equine clinical relevance has not been determined**

Zimeta™ (dipyrone injection) is the FIRST and ONLY drug FDA-approved for the control of pyrexia (fever) in horses

Mirataz is the FIRST and ONLY FDA-approved transdermal medication for the management of weight loss in cats

### Important Safety Information:

Zimeta™ (dipyrone injection) should not be used more frequently than every 12 hours. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals. Not for use in humans, avoid contact with skin and keep out of reach of children. Take care to avoid accidental self-injection and use routine precautions when handling and using loaded syringes. Prior to use, horses should undergo a thorough history and physical examination. Monitor for clinical signs of coagulopathy and use caution in horses at risk for hemorrhage. Concomitant use with other NSAIDs, corticosteroids and nephrotoxic drugs, should be avoided. As a class, NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. The most common adverse reactions observed during clinical trials were Elevated Serum Sorbitol Dehydrogenase (SDH), Hypoalbuminemia and Gastric Ulcers. For complete safety information, see the product insert at the end of the presentation.
Select Summary Financials

December 31, 2020  |  Quarter  |  FY 2020
--- | --- | ---
**Revenues** | | |
Net product revenues | $0.1 | $0.9
Revenue from asset sale | $0.0 | $38.7
Royalty revenue | $0.1 | $0.5
Contract manufacturing | $0.2 | $1.6
Partner licensing revenue | $0.5 | $0.5
**Total revenues** | $1.0 | $42.2

**Operating costs and expenses** | | |
Cost of product revenues | $0.3 | $3.9
Contract manufacturing costs | $0.0 | $0.7
Research and Development | $7.6 | $31.3
Selling, General and Administrative | $3.3 | $22.0
Restructuring costs | $0.0 | $4.2
**Total cash operating costs and expenses** | $11.3 | $62.1
**Total operating costs and expenses** (including stock-based compensation) | $9.8 | $54.5

**Total cash, cash equivalents, and investments** | $59.9 | $59.9

Capital Structure

**Shares Outstanding**

**Options**

Market Cap

$203.1M

1. As of Mar 10, 2021
2. As of Dec 31, 2020
3. As of close of market Mar 12, 2021

Aegis Capital  Nathan Weinstein  nweinstein@aegiscap.com
Alliance Global Partners  Ben Haynor  bhaynor@allianceg.com
Barclays  Balaji Prasad  Balaji.Prasad@barclays.com
Cantor Fitzgerald  Brandon Folkes  brandon.folkes@cantor.com
Guggenheim Securities  David Westenberg  david.westenberg@GuggenheimPartners.com
H.C. Wainwright & Co.  Swayampakula Ramakanth  sramakanth@hcwresearch.com
Lake Street Capital Markets  Brooks O’Neil  brooks.oneil@akstreetcm.com
Stifel  Jonathan Block  blockj@stifel.com
Compelling Value Proposition

- First three approvals validate business model
- Successful development track record - 9 positive pilot studies in a row
- Runway through early 2023
- Capital to achieve key pipeline catalysts
- Reduction in operating expenditures under new model
- Quarterly opex of ~$10M expected through 2021
- Deep pipeline in development
- Multiple potential blockbuster launches anticipated in next three years
- IP platform to maximize program value
- Partnership-focused model maximizes product opportunity
- Mirataz and KIND-030 agreements underscore demand for assets
- Strong capital position provides ability to optimize partnership terms

Focus on highest value biologics

Capital-efficient model reduces financing needs

Partnerships to maximize product value

Deep pipeline targets large markets

Quarterly opex of ~$10M expected through 2021
Recent & Upcoming Catalysts for Late Stage Pipeline

- Tirnovetmab (IL-31) pivotal study for canine atopic dermatitis commenced in 4Q 2020
- KIND-030 pivotal efficacy study for parvovirus in dogs to complete in 2Q 2021
- Second pilot study for IL-4R program for canine atopic dermatitis commenced in 3Q 2020
- Positive results from pilot study for anti-TNF antibody in 4Q 2020
- Multiple blockbuster approvals anticipated in next several years
<table>
<thead>
<tr>
<th></th>
<th>KindredBio Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Focus on innovative biologics – the future of veterinary medicine</td>
</tr>
<tr>
<td>2</td>
<td>Leveraging validated human targets to maximize probability of success</td>
</tr>
<tr>
<td>3</td>
<td>Attractive ROI potential, with cost of development 100 times lower than human markets</td>
</tr>
<tr>
<td>4</td>
<td>Deep pipeline in development. Three approvals validate development model</td>
</tr>
<tr>
<td>5</td>
<td>Strong, late-stage pipeline for canine dermatitis</td>
</tr>
<tr>
<td>6</td>
<td>Broad intellectual portfolio &amp; state-of-the-art manufacturing capabilities</td>
</tr>
</tbody>
</table>
For investor inquiries:
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438

Corporate Office:
1555 Bayshore Hwy, Suite 200
Burlingame, CA 94010
Tel (650) 701-7901

San Diego Office:
591 Camino De La Reina, Ste 407
San Diego, CA 92108
Zimeta™ (dipyrone injection)

500mg/mL injection

For intravenous use in horses

Non-steroidal anti-inflammatory drug (NSAI)

CAUTION: Federal law (U.S.A.) restricts this drug to use by or on the order of a licensed veterinarian.

Description: Dipyrone belongs to the pyrazole class of non-steroidal anti-inflammatory (NSAI) drugs. Chemically, Dipyrone is N-[2-(N-Naphthylmethyl)piperazine-1-yl)acetamide. Each ml of this clear sterile solution for intravenous injection contains 500mg dipyrone and 10mg benzyl alcohol in water.

The structural formula of dipyrone is:

\[
\text{C}_6\text{H}_4\text{CH}_{\text{2}}\text{NH} = \text{C} = \text{O} + \text{H}_2\text{O} \rightarrow \text{C}_6\text{H}_4\text{CH}_{\text{2}}\text{NH} = \text{C} = \text{O} + \text{H}_2\text{O}
\]

Molecular formula: \( \text{C}_6\text{H}_4\text{N}_2\text{O}_4 \)

Molecular Weight: 135.14

Indication: Zimeta™ (dipyrone injection) is indicated for the control of pyrexia in horses.

Dosage and Administration: Always provide the Client Information Sheet with the prescription. Administer Zimeta by intravenous injection, once or twice daily, at 12-hour intervals, for up to three days (at a dosage of 5 mg/kg IM or IV [2 mg/kg IM or IV]). The overall number of dose and duration of treatments with Zimeta is dependent on the response observed (fever reduction). Zimeta may be administered by personnel other than a veterinarian or its authorized representative, provided that said personnel are knowledgeable about the indications and contraindications for the use of this product, and are able to recognize, report, and institute appropriate therapy in case of any adverse reactions, as well as the proper use of the Client Information Sheet.

Contraindications: Do not use in horses with hypersensitivity to dipyrone or dipyrone-related substances. Do not use in horses with known or suspected liver disease or failure.

Warnings: Do not use in horses intended for food consumption. Do not use in pregnant or lactating ponies. Do not use in animals with a history of cardiovascular disease, including arrhythmias or other heart disease.

Human Concerns: Care should be taken to ensure that dipyrone is not administered intravenously into humans as studies have indicated that dipyrone can cause gastrointestinal damage in humans.

For use in horses only. Do not use in horses intended for food consumption. Do not use in pregnant or lactating ponies.

Adverse Reactions: Adverse reactions reported in a controlled clinical trial of 107 horses with fever, ranging in age from 1 to 3 years of age, treated with Zimeta (n=107) and control product (n=31) are summarized in the following Table.1. The control product was a vehicle control (isopropyl mycopore) with additional ingredients added as a vehicle to mask the administration. Vials may have experienced more than one of the adverse observed reactions during the field study. Horses may have received one or more doses of Zimeta during the field study. The control product was only administered once.

Table 1: Adverse Reactions Reported During the Field Study with Zimeta

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Zimeta (dipyrone injection)</th>
<th>Control Product (Vehicle)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinically Serious Infections (Diarrhoea)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>2 (2%)</td>
<td>5 (16%)</td>
</tr>
<tr>
<td>Gastric Ulcers</td>
<td>4 (4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Hypersensitivity Muscle Right Dorsal Colon</td>
<td>2 (2%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Elevated Activated Partial Thromboplastin Time (APTT)</td>
<td>6 (6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Injection Site Reaction</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>8 (8%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Horses with elevated SG1, hyperpyrexia, prolonged APTT, or increased c-reactive did not show associated clinical signs. One horse exhibited an exacerbation of pre-existing hypoaemia with aortic stenosis; the horse also showed concurrent elevation in SG1. Two horses that received Zimeta were diagnosed with gastric ulcers. One horse that received 4 doses of Zimeta was diagnosed with grade 1 gastric ulceration and hypoaemia of the mucosa of the right cranial base and protrusion recession which was performed following euthanasia due to a disease unrelated to treatment (torticollis and obtundation). This horse was previously treated with a different NSAID prior to enrollment in the study. A second horse that enrolled in the study due to a mandibular facial wound, and received two doses of Zimeta, was diagnosed with grade 1 gastric ulceration 4 days following completion of the field study.

In the field study, Zimeta was used concomitantly with other therapies, including antibiotics.

Information for Owners or Persons Treating Horses: A Client Information Sheet should be provided to the person treating the horse. Treatment administrators and carers should be aware of the potential for adverse reactions, and the clinical signs associated with NSAID-induced adverse reactions. Adverse reactions may include colic, diarrhoea, and decreased appetite. Serious adverse reactions can occur without warning and, in some instances, result in death. Clients should be advised to discontinue NSAID therapy and contact their veterinarian immediately if any signs of intolerance are apparent.

Clinical Pharmacology: Dipyrone is a water soluble para-aminophenol derivative that functions as a non-steroidal anti-inflamatory drug (NSAI) and anti-inflammatory drug. In vitro, the compound is known to inhibit prostaglandin synthesis, which is thought to be responsible for the anti-inflammatory and analgesic effects of the drug. In vivo, dipyrone is known to inhibit prostaglandin synthesis, which is thought to be responsible for the anti-inflammatory and analgesic effects of the drug. In vivo, dipyrone is known to inhibit prostaglandin synthesis, which is thought to be responsible for the anti-inflammatory and analgesic effects of the drug.

Zimeta should be given intravenously to horses only. Zimeta is not for use in horses intended for human food consumption. Do not use in animals with a history of cardiovascular disease, including arrhythmias or other heart disease.

Using Zimeta in horses:
- **Dosage and Administration:** Refer to the product label for the proper dosage and administration instructions.
- **Contraindications:** Do not use in horses with a history of cardiovascular disease, including arrhythmias or other heart disease.
- **Warnings:** Do not use in pregnant or lactating ponies. Do not use in animals with a history of cardiovascular disease, including arrhythmias or other heart disease.

**NOTICE:** The use of Zimeta in horses is intended for intravenous administration only. Do not use in animals intended for human food consumption. Do not use in horses with a history of cardiovascular disease, including arrhythmias or other heart disease.
**Zimeta - Prescribing Information**

Tell your veterinarian your horse has been prescribed the following medicinal problem:
- High blood pressure (diabetes mellitus) or other MABEs
- High blood pressure (diabetes mellitus) or other MABEs
- High blood pressure (diabetes mellitus) or other MABEs

Tell your veterinarian if you plan to breed your horse; if your mare is pregnant or nursing, call 1-888-570-0811.

**WHAT ARE THE POSSIBLE SIDE EFFECTS THAT MAY OCCUR IN MY HORSE DURING ZIMETA THERAPY?**

Zimeta should not be given at the same time as other MABEs (e.g., aspirin, phenylbutazone, diclofenac, ketoprofen, flunixin, or flunixin) or other antinflammatories.

**CAN ZIMETA BE GIVEN WITH OTHER MEDICATIONS?**

Horses should be given at the same time as other MABEs (e.g., aspirin, phenylbutazone, diclofenac, ketoprofen, flunixin, or flunixin) or other antinflammatories. If your veterinarian prescribes Zimeta with other medications, please follow your veterinarian’s instructions.

**WHAT DO I DO IF MY HORSE RECEIVES MORE THAN THE PRESCRIBED AMOUNT OF ZIMETA?**

Consult your veterinarian if your horse receives more than the prescribed amount of Zimeta.

**WHAT ELSE SHOULD I KNOW ABOUT ZIMETA?**

This sheet provides a summary of information about Zimeta (dexamethasone and prednisolone). If you have any questions or concerns about the use of Zimeta, you should contact your veterinarian.

As with all prescribed medicines, Zimeta should only be given to the horse for which it is prescribed. If you do not give your horse only the dose that is prescribed, you may be at risk of toxicity or anaphylaxis.

It is important to periodically review your horse’s temperament and record your veterinarian’s recommendations. If your veterinarian determines your horse is not responding to the treatment, you should contact your veterinarian immediately.

Manufactured for:
Kindred Biosciences, Inc.
1555 Bayshore Blvd., Suite 200
Burlington, MA 01803

Zimeta is a trademark of Kindred Biosciences, Inc.
©2021 Kindred Biosciences, Inc. All rights reserved.

**Storage Information:** Store at controlled room temperature (15°C to 30°C [59°F to 86°F]) with excipients permitted between 15°C and 30°C (59°F and 86°F); protect from light. Multi-dose vials: use within 30 days of first puncture.

Approved by FDA under NADA # 141-513
NDC 66079-242-01

Manufactured for:
Kindred Biosciences, Inc.
1555 Bayshore Blvd., Suite 200
Burlington, MA 01803

For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Kindred Biosciences, Inc. at 1-888-404-2542.

Zimeta® is a trademark of Kindred Biosciences, Inc.
©2021 Kindred Biosciences, Inc. All rights reserved.
Rev. 09-2017
KDB0322_ZIF-11


3. FAM/VR:8/06/21 Final